Histone deacetylase inhibitors in oncology

Cancer Chemotherapy and Biotherapy: Principles and Practice

Volumn , Issue , 2011, Pages 1058-1090

  Rahman, Fahd ^a   Robey, Robert W ^b   Bates, Susan E ^b   Piekarz, Richard L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961133356     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (193)

1. Reddy P, Sun Y, Toubai T., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562-2573.
2. Dowdell K, Pesnicak L, Hoffmann V., et al. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 2009;37:487-494.
3. Hahnen E, Hauke J, Tränkle C., et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008;17:169-184.
4. Lane A, Chabner B. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-5468.
5. Dokmanovic M, Clarke C, Marks P. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-989.
6. Bolden J, Peart M, Johnstone R. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784.
7. Schrump D. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009;15:3947-3957.
8. Ellis L, Atadja P, Johnstone R. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-1420.
9. Glozak M, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-5432.
10. Miller R, Rubinstein J. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 1995;56:112-115.
11. Ida K, Kitabayashi I, Taki T., et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 1997;90:4699-4704.
12. Sobulo O, Borrow J, Tomek R., et al. MLL is fused to CBP, a histone acetyltransferase, in therapyrelated acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 1997;94:8732-8737.
13. Gayther S, Batley S, Linger L., et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24:300-303.
14. Ward R, Johnson M, Shridhar V., et al. CBP truncating mutations in ovarian cancer. J Med Genet 2005;42:514-518.
15. Friend C, Scher W, Holland J., et al. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971;68:378-382.
16. Hoffman R, Murnane M, Benz EJ., et al. Induction of erythropoietic colonies in a human chronic myelogenous leukemia cell line. Blood 1979;54: 1182-1187.
17. Lozzio C, Lozzio B, Machado E., et al. Effects of sodium butyrate on human chronic myelogenous leukaemia cell line K562. Nature 1979;281: 709-710.
18. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982;42:65-82.
19. Burgess A, Ruefli A, Beamish H., et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004;23:6693-6701.
20. Ma X, Ezzeldin H, Diasio R. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009;69:1911-1934.
21. Marks P, Richon V, Miller T., et al. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-168.
22. Sánchez-Pacheco A, Martínez-Iglesias O, Méndez-Pertuz M., et al. Residues K128, 132, and 134 in the thyroid hormone receptor-alpha are essential for receptor acetylation and activity. Endocrinology 2009;150:5143-5152.
23. Kawamura T, Ono K, Morimoto T., et al. Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem 2005;280:19682-19688.
24. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-253.
25. Della Ragione F, Criniti V, Della Pietra V., et al. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 2001;499: 199-204.
26. Hoshino I, Matsubara H, Akutsu Y., et al. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep 2007;18:585-592.
27. Peart M, Smyth G, van Laar R., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:3697-3702.
28. Sandor V, Senderowicz A, Mertins S., et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83:817-825.
29. Atadja P, Gao L, Kwon P., et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004;64:689-695.
30. Gui C, Ngo L, Xu W., et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101:1241-1246.
31. Richon VM, Sandhoff TW, Rifkind RA., et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-10019.
32. Burgess AJ, Pavey S, Warrener R., et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001;60:828-837.
33. Qiu L, Burgess A, Fairlie DP., et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-2083.
34. Glaser K, Staver M, Waring J., et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-163.
35. Prystowsky M, Adomako A, Smith R., et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009;218:467-477.
36. Robbins AR, Jablonski SA, Yen TJ., et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005;4:717-726.
37. Rosato RR, Maggio SC, Almenara JA., et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006;69:216-225.
38. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63:3637-3645.
39. Hsiao C, Li W, Lou T., et al. Fetal hemoglobin induction by histone deacetylase inhibitors involves generation of reactive oxygen species. Exp Hematol 2006;34:264-273.
40. Dai Y, Rahmani M, Dent P., et al. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25:5429-5444.
41. Zhao Y, Lu S, Wu L., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006;26:2782-2790.
42. Faiola F, Liu X, Lo S., et al. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 2005;25:10220-10234.
43. Okabe S, Tauchi T, Nakajima A., et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007;16:503-514.
44. Ray S, Lee C, Hou T., et al. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 2008;36:4510-4520.
45. Krämer O, Baus D, Knauer S., et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 2006;20:473-485.
46. Marks P, Xu W. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107:600-608.
47. Yu X, Guo ZS, Marcu MG., et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513.
48. Fuino L, Bali P, Wittmann S., et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-984.
49. Nimmanapalli R, Fuino L, Bali P., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-5135.
50. Edwards A, Li J, Atadja P., et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007;6:2515-2524.
51. Nishioka C, Ikezoe T, Yang J., et al. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008;32:1382-1392.
52. Rosato R, Almenara J, Maggio S., et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008;7: 3285-3297.
53. Adimoolam S, Sirisawad M, Chen J., et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 2007;104:19482-19487.
54. Geng L, Cuneo K, Fu A., et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-11304.
55. Zhang F, Zhang T, Teng Z., et al. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 2009;8:823-831.
56. Wang S, El-Deiry W. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-8633.
57. Guo F, Sigua C, Tao J., et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004;64:2580-2589.
58. Kwon S, Ahn S, Kim Y., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 2002;277:2073-2080.
59. Kim Y, Park J, Lee J., et al. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis. 2004;25:1813-1820.
60. Park S, Kim M, Kim H., et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol 2009;77:1328-1336.
61. Rippo M, Moretti S, Vescovi S., et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004;23:7753-7760.
62. Jin Z, El-Deiry W. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-163.
63. Zhang X, Gillespie S, Borrow J., et al. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004;3:425-435.
64. Fandy T, Shankar S, Ross D., et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005;7:646-657.
65. Chen S, Dai Y, Pei X., et al. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009;29:6149-6169.
66. Hideshima T, Bradner J, Wong J., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102:8567-8572.
67. Witt O, Deubzer H, Milde T., et al. HDAC family: What are the cancer relevant targets? Cancer Lett 2009;277:8-21.
68. Weichert W, Röske A, Niesporek S., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14:1669-1677.
69. Huang B, Laban M, Leung C., et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
70. Kawaguchi Y, Kovacs J, McLaurin A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-738.
71. Demary K, Wong L, Spanjaard R. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 2001;163:103-107.
72. Davis T, Kennedy C, Chiew Y., et al. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 2000;6:4334-4342.
73. Phiel C, Zhang F, Huang E., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-36741.
74. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
75. Richon VM, Emiliani S, Verdin E., et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003-3007.
76. Nakajima H, Kim YB, Terano H., et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241: 126-133.
77. Ueda H, Nakajima H, Hori Y., et al. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotech Biochem 1994;58:1579-1583.
78. Lee JS, Paull K, Alvarez M., et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol Pharmacol 1994;46:627-638.
79. Furumai R, Matsuyama A, Kobashi N., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-4921.
80. Gore S, Carducci M. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 2000;9:2923-2934.
81. Atmaca A, Al-Batran SE, Maurer A., et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-182.
82. Munster P, Marchion D, Bicaku E., et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-1985.
83. Kelly WK, Richon VM, O 'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588.
84. Kelly WK, O 'Connor OA, Krug LM., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931.
85. Rubin E, Agrawal N, Friedman E., et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12: 7039-7045.
86. Steele N, Plumb J, Vidal L., et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804-810.
87. Warren K, McCully C, Dvinge H., et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol 2008;62: 433-437.
88. Giles F, Fischer T, Cortes J., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635.
89. Ellis L, Pan Y, Smyth G., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-4510.
90. Prince H, Bishton M, Johnstone R. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009;5:601-612.
91. Woo S, Gardner E, Chen X., et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009;15:1496-1503.
92. Fouladi M, Furman W, Chin T., et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children 's Oncology Group report. J Clin Oncol 2006;24:3678-3685.
93. Shiraga T, Tozuka Z, Ishimura R., et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005;28: 124-129.
94. Berg S, Stone J, Xiao J., et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol 2004;54:85-88.
95. Gore L, Rothenberg M, O 'Bryant C., et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14:4517-4525.
96. Ryan Q, Headlee D, Acharya M., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-3922.
97. Acharya M, Karp J, Sausville E., et al. Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006;24:367-375.
98. Siu L, Pili R, Duran I., et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-1947.
99. Prince H, Bishton M, Harrison S. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15:3958-3969.
100. Bates S, Zhan Z, Steadman K., et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148:256-267.
101. Kummar S, Gutierrez M, Gardner ER., et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13:5411-5417.
102. Fantin V, Loboda A, Paweletz C., et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68:3785-3794.
103. Garcia-Manero G, Yang H, Bueso-Ramos C., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-1066.
104. Schrump DS, Fischette MR, Nguyen DM., et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008;14:188-198.
105. Marquard L, Petersen K, Persson M., et al. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS 2008;116:382-392.
106. Sandor V, Bakke S, Robey RW., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728.
107. de Bono JS, Kristeleit R, Tolcher A., et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008;14:6663-6673.
108. Duvic M, Talpur R, Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
109. Rowinsky EK, de Bono J, Deangelo DJ., et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2005;23:3131.
110. Beck J, Fischer T, George D., et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of ORAL LBH589B: A novel histone deacetylase (HDAC) inhibitor. J Clin Oncol (Meeting Abstracts) 2005;23:3148.
111. Fischer T, Patnaik A, Bhalla K., et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2005;23:3106.
112. Kelly WK, DeBono J, Blumenschein G., et al. Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2009;27:3531.
113. Kristeleit R, Fong P, Aherne G., et al. Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clin Lung Cancer 2005;7 Suppl 1: S19-S30.
114. Molife R, Fong P, Scurr M., et al. HDAC inhibitors and cardiac safety. Clin Cancer Res2007;13:1068; author reply 1068-1069.
115. Piekarz RL, Frye AR, Wright JJ., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-3773.
116. O 'Mahony D, Piekarz R, Bandettini W., et al. Cardiac involvement with lymphoma: a review of the literature. Clin Lymphoma Myeloma 2008;8:249-252.
117. Olsen E, Kim Y, Kuzel T., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-3115.
118. Zhang L, Lebwohl D, Masson E., et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008;26:332-333; discussion 333-334.
119. Shah MH, Binkley P, Chan K., et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003.
120. Strevel E, Siu L. Cardiovascular toxicity of molecularly targeted agents. Eur J Cancer 2009;45(Suppl 1):318-331.
121. Fingert H, Varterasian M. Cardiac safety, risk management, and oncology drug development. Clin Cancer Res 2006;12:3646-3647.
122. Rock E, Finkle J, Fingert H., et al. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 2009;157:827-836; 836.e821.
123. Cabell C, Bates S, Piekarz R., et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. ASH Ann Meet Abst 2009;114:3709.
124. Munster P, Rubin E, Van Belle S., et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009;15:7077-7084.
125. Ramalingam S, Belani C, Ruel C., et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4:97-101.
126. Stadler WM, Margolin K, Ferber S., et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourinary Cancer 2006;5:57-60.
127. Piekarz R, Frye R, Turner M., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-5417.
128. Kanji Z, Jung K. Evaluation of an electrolyte replacement protocol in an adult intensive care unit: a retrospective before and after analysis. Intensive Crit Care Nurs 2009;25:181-189.
129. Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma 2002;43:1297-1302.
130. Zain JM, Foss F, Kelly WK., et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol (Meeting Abstracts) 2009;27:8580.
131. Duvic M, Talpur R, Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
132. Sherman EJ, Fury MG, Tuttle RM., et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol (Meeting Abstracts) 2009;27:6059.
133. Wise L, Turner K, Kerr J. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 2007;80:57-68.
134. Ritchie D, Piekarz R, Blombery P., et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009;94:1618-1622.
135. Edelstein L, Micheva-Viteva S, Phelan B., et al. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 2009;25:883-887.
136. Piekarz RL, Robey R, Sandor V., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-2868.
137. Pohlman B, Advani R, Duvic M., et al. Final results of a phase ii trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous t-cell lymphoma. ASH Ann Meet Abst 2009;114:920.
138. Piekarz R, Wright J, Frye R., et al. Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral t-cell lymphoma (PTCL). ASH Ann Meet Abst 2009;114:1657.
139. Molife R, Patterson S, Riggs C., et al. Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer. Am Soc Clin Oncol Prostate Cancer Symposium. 2006.
140. Whitehead RP, McCoy S, Wollner IS., et al. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. J Clin Oncol 2006;24:170S-170S.
141. Mann B, Johnson J, Cohen M., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-1252.
142. Mann B, Johnson J, He K., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007;13:2318-2322.
143. O 'Connor O, Heaney M, Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-173.
144. Crump M, Coiffier B, Jacobsen E., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Onco. 2008;19:964-969.
145. Richardson P, Mitsiades C, Colson K., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49:502-507.
146. Marshall J, Rizvi N, Kauh J., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-332.
147. Kim Y, Whittaker S, Demierre MF., et al. Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study. ASH Ann Meet Abst 2008;112:263.
148. Whitehead R, Rankin C, Hoff P., et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2009;27:469-475.
149. Gojo I, Jiemjit A, Trepel JB., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-2790.
150. Hauschild A, Trefzer U, Garbe C., et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-(4-[(2-aminophenyl)-carbamoyl]-benzyl)-carbamate in pretreated metastatic melanoma. Melanoma Res 2008;18:274-278.
151. Dickinson M, Ritchie D, DeAngelo D., et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009;147:97-101.
152. Ottmann OG, Spencer A, Prince HM., et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Ann Meet Abst 2008;112:958.
153. Crump M, Andreadis C, Assouline S., et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol (Meeting Abstracts) 2008;26:8528-.
154. Bots M, Johnstone R. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-3977.
155. Badros A, Burger A, Philip S., et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-5257.
156. Weber DM, Jagannath S, Mazumder A., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. ASH Ann Meet Abst 2007; 110:1172.
157. Weber D, Badros AZ, Jagannath S., et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. ASH Ann Meet Abst 2008;112:871.
158. Nguyen DM, Schrump WD, Tsai WS., et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg 2003;125:1132-1142.
159. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004;161:667-674.
160. Camphausen K, Burgan W, Cerra M., et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-321.
161. Camphausen K, Tofilon P. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-4056.
162. Kitazono M, Robey R, Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:3430-3435.
163. Chen J, Zhang M, Ju W., et al. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009;113:1287-1293.
164. Piekarz RL, Robey RW, Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-4643.
165. Petrij F, Dauwerse H, Blough R., et al. Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations. J Med Genet 2000;37:168-176.
166. Taki T, Sako M, Tsuchida M., et al. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997;89:3945-3950.
167. Borrow J, Stanton VJ, Andresen J., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14:33-41.
168. Koshiishi N, Chong J, Fukasawa T., et al. p300 gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer 2004;7:85-90.
169. Mattera L, Escaffit F, Pillaire M., et al. The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways. Oncogene 2009;28:1506-1517.
170. Grignani F, De Matteis S, Nervi C., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-818.
171. Wang J, Hoshino T, Redner R., et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998;95:10860-10865.
172. Choi J, Kwon H, Yoon B., et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-1304.
173. Song J, Noh J, Lee J., et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113:264-268.
174. Ashktorab H, Belgrave K, Hosseinkhah F., et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 2009;54:2109-2117.
175. Elsheikh S, Green A, Rakha E., et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009;69:3802-3809.
176. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
177. Soriano AO, Yang H, Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308.
178. Gore S, Baylin S, Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-6369.
179. Ramalingam S, Maitland M, Frankel P., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2009;28:56-62.
180. Reguart N, Cardona AF, Isla D., et al. Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression. J Clin Oncol (Meeting Abstracts) 2009;27:e19057.
181. Tredaniel J, Descourt R, Moro-Sibilot D., et al. Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study. J Clin Oncol (Meeting Abstracts) 2009;27:8049.
182. Fakih M, Pendyala L, Fetterly G., et al. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009;15:3189-3195.
183. Fouladi M, Park JR, Sun J., et al. A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. J Clin Oncol (Meeting Abstracts) 2008;26:10012.
184. Munster P, Marchion D, Thomas S., et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009;101:1044-1050.
185. Garcia-Manero G, Tambaro FP, Bekele BN., et al. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). ASH Ann Meet Abst 2009; 114:1055.
186. Grant S, Kolla S, Sirulnik LA., et al. Phase I trial of vorinostat (SAHA) in combination with alvocidib (Flavopiridol) in patients with relapsed, refractory or (Selected) poor prognosis acute leukemia or refractory anemia with excess blasts-2 (RAEB-2). ASH Ann Meet Abst 2008;112:2986.
187. Dummer R, Hymes K, Sterry W., et al. Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: a phase I study. J Clin Oncol (Meeting Abstracts) 2009;27:8572.
188. Harrison SJ, Quach H, Yuen K., et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. ASH Ann Meet Abst 2008;112:3698.
189. Finkler NJ, Dizon DS, Braly P., et al. Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC). J Clin Oncol (Meeting Abstracts) 2008;26:5519.
190. Garcia-Manero G, Yang AS, Klimek V., et al. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). J Clin Oncol (Meeting Abstracts) 2007;25:7062.
191. Hurwitz H, Nelson B, O 'Dwyer PJ., et al. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J Clin Oncol (Meeting Abstracts) 2008;26:4625.
192. Konduri K, Spira AI, Jotte RM., et al. Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC. J Clin Oncol (Meeting Abstracts) 2009;27:e14545.
193. Juergens RA, Vendetti F, Coleman B., et al. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts)